Bextra Decision Shows Effort To Improve Drug Safety Transparency, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement about the Bextra withdrawal and the addition of "black box" warnings to all prescription NSAIDs was part of FDA's ongoing effort "to improve communication about emerging drug safety concerns," CDER Acting Deputy Director Throckmorton says.